News
3 Stocks That Can Benefit from a Santa Claus Rally
Almost like clockwork, Halloween ended, stores started setting up for the all-important holiday shopping season, and the stock market started what could potentially end up as one heck of an early
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY) are both eyeing the same pie, and they're both serious about getting a big slice. But it isn't a hot market for drugs to treat a single disease
3 Growth Stocks to Buy Right Now Without Any Hesitation
You've probably heard all the old expressions about acting too quickly. "Haste makes waste" and "Look before you leap" are two that readily come to mind. However, there's also danger in waiting too
Where Will Novavax Be in 3 Years?
A lot can happen in just a few years, and Novavax (NASDAQ: NVAX) is the proof of that. Three years ago, the company was rushing toward the coronavirus vaccine finish line -- and the shares were
Why Coherus BioSciences Was Plummeting This Week
A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of
2 Top Biotech Stocks to Buy Right Now
It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's
Got $5,000? Get the Most Bang for Your Buck With These 4%-Plus Dividend Yield Stocks
The average stock in the S&P 500 has a dividend that only yields 1.6%. However, investors can secure much higher yields than that without taking on much extra risk. If you've got $5,000 that you can
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth
AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock?
For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q3 2023 Earnings CallNov 09, 2023, 9:00 a.m. ET
Operator
Source Fool.com
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
Last year, the Federal Reserve began hiking interest rates in an effort to slow down the economy. Today, interest rates are at their highest levels since the early 2000s. For many businesses, an
Is Sarepta Therapeutics Stock a Bad-News Buy?
Investing in biotech stocks is risky. And one of the more volatile ones of late is Sarepta Therapeutics (NASDAQ: SRPT). Shares of the company crashed last week after it released results from phase 3
2 Soaring Stocks to Buy and Hold
Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic
Invitae (NVTA) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q3 2023 Earnings CallNov 08, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q3 2023 Earnings CallNov 08, 2023, 8:00 a.m. ET
Operator
Source Fool.com
1 Gene Therapy Stock to Buy and Hold for the Long Haul
Biotech companies working on gene therapies have made significant strides lately, but many of them remain relatively risky stocks. Still, gene therapies have the potential to help transform medicine
Why CRISPR Therapeutics Stock Could Be About to Take Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its
EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update
MannKind (MNKD) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q3 2023 Earnings CallNov 07, 2023, 5:00 p.m. ET
Operator
Source Fool.com
Why Sage Therapeutics Stock Sank Today
It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter
Why Coherus Biosciences Stock Dropped Today
Shares of Coherus Biosciences (NASDAQ: CHRS) were down by about 30% as of 3:25 p.m. ET Tuesday after the company announced disappointing third-quarter results and lowered its full-year guidance.
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes